##plugins.themes.bootstrap3.article.main##

Jiawen Wang Mengzhen Yuan Yi Zou Yue Yu JiaJia Yu Jiang Liu Peng Yu Zhen Liu Cen Xiang YuOu Teng

Abstract

Metabolic dysfunction-associated steatohepatitis(MASH) is a common liver disease worldwide and can develop into liver cirrhosis and liver cancer. Current treatment is limited, and the only drug Rezdiffra has limited effects. GFT-505 performed well as a PPAR agonist in stage II, but not as expected in stage III. We replaced the sulfur atom of GFT-505 with selenium to obtain compound 4c. Study evaluating the effect of 4c on the MASH mouse model induced by MCD. The results showed that 4c improved MASH through multi-target synergy and reduced TG and ALT better than GFT-505. This finding provides a theoretical basis and new ideas for the development of novel multi-target anti-MASH drugs.

Downloads

Keine Nutzungsdaten vorhanden.

##plugins.themes.bootstrap3.article.details##

Rubrik
Articles